Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Bone Metastases From Solid Tumors × Clear all
NCT04859569 2021-06-07

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Luye Pharma Group Ltd.

Phase 3 Unknown
850 enrolled
Other solid neoplasm

Bone Metastases From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡